Use of high dose factor VIIa in hemophilia patients.
Hedner
U
U
Novo Nordisk, A/S, Målov, Denmark.
D000293:Adolescent; D000328:Adult; D000818:Animals; D001777:Blood Coagulation / Q000502:physiology; D016063:Blood Loss, Surgical / Q000517:prevention & control; D002648:Child; D002986:Clinical Trials as Topic; D004211:Disseminated Intravascular Coagulation / Q000209:etiology; D004789:Enzyme Activation; D005164:Factor IX / Q000276:immunology / Q000627:therapeutic use; D005169:Factor VIII / Q000276:immunology / Q000627:therapeutic use; D015942:Factor VIIa / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D006395:Hemarthrosis / Q000517:prevention & control / Q000628:therapy; D006467:Hemophilia A / Q000628:therapy*; D002836:Hemophilia B / Q000628:therapy; D006470:Hemorrhage / Q000517:prevention & control / Q000628:therapy; D006801:Humans; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D015337:Multicenter Studies as Topic; D019106:Postoperative Hemorrhage / Q000517:prevention & control; D016032:Randomized Controlled Trials as Topic; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D013552:Swine; D013917:Thrombin / Q000378:metabolism; D016896:Treatment Outcome
D011993:Recombinant Fusion Proteins; D005169:Factor VIII; D005164:Factor IX; D015942:Factor VIIa; D013917:Thrombin